TH60763A - Recombinant PoX Virus, a vaccine of the virus, causing the pig reproductive and respiratory syndrome (PRRSV). - Google Patents

Abstract

DC60 (09/08/44) What is being discussed is recombinant vectors, such as viruses. For example, poxviruses, such as avipoxvirus, which have external DNA from the swine reproductive and respiratory syndrome virus (SPSV). Also mentioned are immunological mixtures containing recombinant poxviruses for inducing an immune response in host animals that receive the immunological mixture. Also mentioned are methods for treating or preventing SPSV disease by administering a concoction of immunological mixture to animals requiring treatment or susceptible to SPSV infection. What is being discussed is recombinant vectors, such as viruses. For example, poxviruses, such as avipoxvirus, which have external DNA from the swine reproductive and respiratory syndrome virus (SPSV). Also mentioned are immunological mixtures. The immunotherapy approach using recombinant potent viruses to induce an immune response in host animals administered with an immunotherapy mixture, as mentioned earlier, is a method for treating or preventing swine reproductive and respiratory syndrome (SRS) by administering a manufactured immunotherapy mixture to animals requiring treatment or susceptible to SRS infection.

Claims (18)

1. Recombinant avipox viruses consist of DNA that is complementary to the genomic RNA of the swine reproductive and respiratory syndrome virus (PRRSV). 2. A recombinant avipox virus of claim 1 that is a foulpox virus. 3. A recombinant avipox virus of claim 1 that is a canarypox virus. 4. Recombinant avipox virus of claim 1, which is ALVAC. 5. A recombinant avipox virus of one of the claims 1 through 4, where the DNA complementary to the genomic RNA of porcine reproductive and respiratory syndrome virus encodes and is characterized as PRRSV glycoprotein, membrane protein, or capsid. 6. A recombinant avipox virus of claim 5, in which it incorporates DNA that is complementary to the genomic RNA of the swine reproductive and respiratory syndrome virus (SRLS) corresponding to open frame 5 (ORF5). 7. A recombinant avipox virus of claim 5, in which it incorporates DNA that is complementary to the genomic RNA of the swine reproductive and respiratory syndrome virus (SRLS) corresponding to open frame 5 (ORF5) and 3 (ORF3). 8. A recombinant avipox virus of claim 5, in which it incorporates DNA that is complementary to the genomic RNA of the swine reproductive and respiratory syndrome virus (SRLS) corresponding to open frame 5 (ORF5) and 6 (ORF6). 9. A recombinant avipox virus of claim 5, in which it incorporates DNA that is complementary to the genomic RNA of the swine reproductive and respiratory syndrome virus (SRLS) corresponding to open frames 5 (ORF5), 3 (ORF3), and 6 (ORF6). 10. A recombinant avipox virus of claim 7 or 8, where ORF5 and ORF6 or ORF3 are contiguous. 11. Recombinant avipox viruses of claim 4 that are vCP1618, vCP1619, vCP1626, or vCP1643. 12. Immunological mixture for inducing an immune response in hosts grown with an immunological mixture. The immunological mixture contains at least one vector and recombinant virus of one of the claims 1 through 11. 13. A PRRS vaccine containing at least one carrier and recombinant virus of any one of the claims 1 through 11. 14. Vaccines under claim 13 that include an adjuvant. 15. Vaccine of claim 14 where the adjuvant is a polymer of acrylic or methacrylic acid or a copolymer of maleic anhydride and alkenyl derivatives. 16. The vaccine under claim 15, where the adjuvant is a carbomer, should be Carpobol R. 17. The vaccine under claim 15, where the adjuvant is carbomer, is EMA R. 18. The swine vaccine compound shall contain at least one vaccine under one of the claims of Rights 13 through 17 and at least one vaccine against at least one other swine pathogen.